Sunday, 20 September 2026European Markets

SEQUANA MEDICAL Stock Bullish Momentum With A 10.69% Jump Today

Loading stream...

(VIANEWS) - The Market ended the session with SEQUANA MEDICAL (SEQUA.BR) jumping 10.69% to €1.78 on Wednesday, after two consecutive sessions in a row of gains. BEL 20 rose 1.52% to €4,029.25, after two successive sessions in a row of losses, on what was an all-around up trend trading session today.

SEQUANA MEDICAL's last close was €1.61, 66.8% under its 52-week high of €4.85.

About SEQUANA MEDICAL

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Ghent, Belgium.

Earnings Per Share

As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-1.32.

Moving Average

SEQUANA MEDICAL's value is above its 50-day moving average of €1.72 and way below its 200-day moving average of €2.85.

Volatility

SEQUANA MEDICAL's last week, last month's, and last quarter's current intraday variation average was 3.58%, 0.45%, and 3.71%.

SEQUANA MEDICAL's highest amplitude of average volatility was 3.58% (last week), 2.02% (last month), and 3.71% (last quarter).

More news about SEQUANA MEDICAL (SEQUA.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com